Report of Foreign Issuer (6-k)
25 Setembro 2020 - 9:12AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the month of: September 2020 (Report
No. 4)
Commission file number: 001- 38041
THERAPIX BIOSCIENCES LTD.
(Translation of registrant’s name into English)
16 Abba Hillel Road
Ramat Gan 5250608, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
Attached hereto and
incorporated by reference herein is the Registrant’s Notice of Special General Meeting of Shareholders, Proxy Statement,
Proxy Card and Voting Instruction Card for the Special General Meeting of Shareholders of the Company to be held on Friday, October
16, 2020 (the “Meeting”).
Only shareholders
of record who hold Ordinary Shares, nominal value NIS 0.10, or American Depositary Shares representing Ordinary Shares, of the
Registrant at the close of business on Monday, September 28, 2020, will be entitled to notice of and to vote at the Meeting and
any postponements or adjournments thereof.
This Report on Form
6-K is incorporated by reference into the registration statements on Form F-3 (File No. 333-225745 and File No. 333-233417) and
on Form S-8 (File No. 333-225773) of the Company, filed with the Securities and Exchange Commission, to be a part thereof from
the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Therapix
Biosciences Ltd.
|
|
|
Date: September
25, 2020
|
By
|
/s/
Oz Adler
|
|
Name:
|
Oz Adler
|
|
Title:
|
Chief Financial
Officer
|
2
Therapix Biosciences (NASDAQ:TRPX)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Therapix Biosciences (NASDAQ:TRPX)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024